Scientists at The Saban Research Institute of Children’s Hospital Los Angeles (CHLA) have discovered that a combination of a survivin inhibitor — survivin is a protein that inhibits apoptosis or cell death — and chemotherapy offers a therapeutic advantage for retinoblastoma cells and tumors.
Through their research using mouse models, the scientists hope their findings will help provide better outcomes for children with retinoblastoma and possibly reduce the amount of chemotherapy needed to help lower long-term adverse effects.
The full study was recently published online in PLOS One.
Click here to read the full press release.
Source: Children's Hospital Los Angeles